Cognition Therapeutics, Inc. (CGTX)
Nasdaq: CGTX · Biological Products, (No Diagnostic Substances) · Purchase, NY · filing with the SEC since 2009
Income statement, as filed
In thousands of US dollars (USD), as filed; per-share figures in US dollars; share counts. The fiscal year ends in December.| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Period ending | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 |
| Report filed | Mar 26, 2026 | Mar 20, 2025 | Mar 26, 2024 | Mar 23, 2023 | Mar 30, 2022 | · |
| For lenders | ||||||
| Net interest income | · | · | -27 | -28 | -893 | -1,751 |
| Research and development | 37,187 | 41,676 | 37,196 | 30,324 | 18,572 | 12,887 |
| General and administrative | 10,612 | 12,290 | 13,528 | 13,227 | 10,026 | 4,520 |
| Total operating expenses | 47,799 | 53,966 | 50,724 | 43,551 | 28,598 | 17,407 |
| Operating income | -47,799 | -53,966 | -50,724 | -43,551 | -28,598 | -17,407 |
| Interest expense | · | · | · | · | 895 | 1,758 |
| Interest income (expense), net | -13 | -25 | -27 | · | · | · |
| Other income (expense), net | 24,312 | 19,995 | 24,936 | 22,154 | 16,882 | 9,568 |
| Income tax expense | 0 | 0 | 0 | 0 | 0 | · |
| Net income | -23,487 | -33,971 | -25,788 | -21,397 | -11,716 | -7,839 |
| Net income to common shareholders | · | · | · | -21,397 | -16,248 | -12,073 |
| Earnings per share, basic | -0.32 | -0.86 | -0.86 | -0.91 | -3.13 | -23.76 |
| Earnings per share, diluted | -0.32 | -0.86 | -0.86 | -0.91 | -3.13 | -23.76 |
| Weighted average shares, basic | 72,766,983 | 39,730,148 | 30,029,087 | 23,640,199 | 5,190,883 | 508,112 |
| Weighted average shares, diluted | 72,766,983 | 39,730,148 | 30,029,087 | 23,640,199 | 5,190,883 | 508,112 |
As filed with the SEC, each figure from the newest report that carries it, and linked to it. Nothing here is computed.A dot is a line not tagged for that period. r restated by the company in a later report; b a share figure put on the newest basis or filed in the wrong unit. Hover a figure for its filing and note.
What each line is, and the XBRL concept behind it
Net interest income interest earned less interest paid
us-gaap:InterestIncomeExpenseNetResearch and development spent on inventing what it sells next
us-gaap:ResearchAndDevelopmentExpenseGeneral and administrative the cost of running the company itself
us-gaap:GeneralAndAdministrativeExpenseTotal operating expenses the running costs together
us-gaap:OperatingExpensesOperating income profit from running the business, before interest and tax
us-gaap:OperatingIncomeLossInterest expense what its borrowing cost
us-gaap:InterestExpenseDebtInterest income (expense), net interest earned less interest paid, outside the business
us-gaap:InterestIncomeExpenseNonoperatingNetOther income (expense), net gains and costs outside the business
us-gaap:OtherNonoperatingIncomeExpenseIncome tax expense tax charged on the period's profit
us-gaap:IncomeTaxExpenseBenefitNet income the profit or loss that belongs to the company's shareholders
us-gaap:NetIncomeLossNet income to common shareholders what is left for common shareholders
us-gaap:NetIncomeLossAvailableToCommonStockholdersBasicEarnings per share, basic net income per share outstanding
us-gaap:EarningsPerShareBasicEarnings per share, diluted net income per share, counting every share that could be issued
us-gaap:EarningsPerShareDilutedWeighted average shares, basic the average count of shares outstanding
us-gaap:WeightedAverageNumberOfSharesOutstandingBasicWeighted average shares, diluted the average count with every share that could be issued
us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding